Irvine Scientific launches new feed media to maximize productivity in large-scale bioproduction
BalanCD CHO Feed 4 is a chemically-defined, animal component-free powder feed for large-scale bioproduction in a variety of high performing CHO cells.
Irvine Scientific has launched BalanCD CHO Feed 4, a chemically defined, animal component-free powder feed for large-scale bioproduction in a variety of high performing CHO cells. When paired with BalanCD CHO Growth A in fed-batch culture systems, up to 20 million viable cells/mL, and antibody titer up to 6g/ L can be achieved.
Recent developments in cell line engineering have resulted in cell lines capable of reaching higher cell densities and productivity rates. To achieve their full production potential these cell lines need nutrient-rich media; however these feeds can be difficult to dissolve and require complicated time-consuming preparation protocols. BalanCD CHO Feed 4 is designed and formulated to prepare easily using a simplified hydration procedure that does not require pH adjustments. BalanCD CHO Feed 4 maintains pH stability in culture and is designed to support growth while minimizing the production of metabolites that adversely affect titer levels; this results in process consistency, significantly higher protein production and protein quality.
“Surveys of large-scale culture media end-users identify time and effort required for mixing powdered media as a top concern. By applying our expertise at media development and formulation we are able to deliver a product that provides performance, flexibility and ease-of-use that facilitates a more robust process.” said Dr Jessie H.-T. Ni, Chief Scientific Officer of Irvine Scientific. “This new Feed is a significant addition to our BalanCD CHO platform that is designed to streamline the development and scale-up process to help our customers get to market faster.”
Related News
-
News WuXi to sell CGT manufacturing unit to US-based Altaris LLC
At the tail end of 2024, Chinese-based CDMO WuXi AppTec announced the signing of their deal with private equity firm Altaris LLC, confirming the sale of WuXi Advanced Therapies, the cell and gene therapy manufacturing arm of WuXi AppTec. -
News Women in Pharma: Our hopes for 2025 and beyond
Our last instalment for 2024 of the Women in Pharma series brings you messages direct from the Informa Markets CPHI team as they discuss the advice and insights they have carried throughout their roles working at CPHI, and what they hope to see for the... -
News CPHI Milan Wrap-Up Report: Conference Highlights
Discover the emerging and trending topics of the pharmaceutical industry with our CPHI Milan Conference Highlights, with exclusive insight from pharmaceutical leaders and experts! -
News BIOSECURE Act not included in key defense spending bill for 2025
On December 7, 2024, the Biden administration revealed the 2025 National Defense Authorization Act, an annual defense bill specifying the budget and expenditures of the US Department of Defense. The controversial BIOSECURE Act was notably missing from ... -
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News Trump 2.0: What does the US election result mean for the healthcare industry?
After Trump won the Presidential election in the US in early November, we take a look at some of the implications a new Trump administration could have on the health and pharmaceutical industry, and on US patients. -
News Women in Pharma: Reflections from Behind the Scenes
In this instalment of our monthly series, the team that brings you the Women in Pharma series each month sits down for a heart-to-heart on what the series means to them, and how they hope to continue their work in the future. -
News Scaling the Industry: CPHI Scale-Up Market interview with YSK Laboratories
For the first time, CPHI Milan hosted the CPHI Start-Up Market, expanding support for emerging and small-sized enterprises in their transition to the next level of growth. In this interview, we spoke with Yuvansh Khokhani, Managing Director of YSK Labo...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance